Agenus launches SaponiQx subsidiary

By The Science Advisory Board staff writers

September 10, 2021 -- Agenus is launching a new subsidiary dedicated to novel adjuvant discovery and vaccine design, the company announced.

The subsidiary, SaponiQx, is building a platform that aims to deliver sustainable manufacturing approaches and a secure supply of known adjuvants. In addition, the platform is designed to discover novel adjuvants and develop vaccines that use optimized antigen-adjuvant pairings, Agenus said.

The subsidiary is collaborating with Ginkgo Bioworks and using Ginkgo's metabolic engineering for novel adjuvant discovery.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.